Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 5 | 2023 | 140 | 3.390 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2023 | 21 | 2.340 |
Why?
|
| Adenocarcinoma | 4 | 2022 | 311 | 1.950 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 461 | 1.320 |
Why?
|
| Neoplasms | 5 | 2022 | 692 | 1.100 |
Why?
|
| Neoplasms, Second Primary | 2 | 2018 | 16 | 0.770 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 244 | 0.750 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 216 | 0.700 |
Why?
|
| Immunotherapy | 2 | 2018 | 80 | 0.650 |
Why?
|
| Indoles | 1 | 2019 | 56 | 0.640 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 44 | 0.640 |
Why?
|
| Image Enhancement | 1 | 2019 | 72 | 0.640 |
Why?
|
| Contrast Media | 1 | 2019 | 138 | 0.620 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 104 | 0.620 |
Why?
|
| Organ Transplantation | 1 | 2018 | 66 | 0.610 |
Why?
|
| Melanoma | 1 | 2018 | 164 | 0.570 |
Why?
|
| Humans | 22 | 2023 | 31981 | 0.490 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 89 | 0.470 |
Why?
|
| Dendritic Cells | 1 | 2014 | 59 | 0.460 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 165 | 0.440 |
Why?
|
| Middle Aged | 12 | 2021 | 11845 | 0.430 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 1324 | 0.420 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3315 | 0.410 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 192 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 370 | 0.410 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 214 | 0.390 |
Why?
|
| Male | 14 | 2021 | 19161 | 0.380 |
Why?
|
| Prognosis | 4 | 2021 | 1505 | 0.380 |
Why?
|
| Female | 14 | 2021 | 19920 | 0.380 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2021 | 33 | 0.370 |
Why?
|
| Pancreas | 2 | 2023 | 104 | 0.370 |
Why?
|
| Aged | 11 | 2022 | 10332 | 0.360 |
Why?
|
| Adult | 8 | 2022 | 9340 | 0.360 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 456 | 0.340 |
Why?
|
| African Americans | 1 | 2015 | 1427 | 0.300 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 85 | 0.260 |
Why?
|
| Retrospective Studies | 4 | 2022 | 3523 | 0.250 |
Why?
|
| Mucin 5AC | 1 | 2023 | 2 | 0.220 |
Why?
|
| Survival Analysis | 2 | 2021 | 488 | 0.200 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2021 | 5 | 0.200 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 38 | 0.200 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 21 | 0.190 |
Why?
|
| Pancreatectomy | 1 | 2021 | 32 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2019 | 111 | 0.180 |
Why?
|
| Malnutrition | 1 | 2020 | 17 | 0.180 |
Why?
|
| GTP Phosphohydrolases | 1 | 2020 | 9 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 14 | 0.180 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 11 | 0.180 |
Why?
|
| United States | 2 | 2022 | 3936 | 0.180 |
Why?
|
| Risk Factors | 2 | 2021 | 3867 | 0.180 |
Why?
|
| Camptothecin | 1 | 2020 | 52 | 0.180 |
Why?
|
| Treatment Failure | 1 | 2020 | 163 | 0.170 |
Why?
|
| Deoxycytidine | 1 | 2020 | 68 | 0.170 |
Why?
|
| Fluorouracil | 1 | 2020 | 82 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 240 | 0.170 |
Why?
|
| Esophagogastric Junction | 1 | 2019 | 7 | 0.170 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 35 | 0.170 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 47 | 0.170 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 221 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 36 | 0.160 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 59 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2020 | 256 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 3998 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2019 | 182 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2019 | 292 | 0.150 |
Why?
|
| Smad4 Protein | 1 | 2017 | 1 | 0.150 |
Why?
|
| Loss of Heterozygosity | 1 | 2017 | 20 | 0.150 |
Why?
|
| Mutation | 2 | 2017 | 488 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 628 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2019 | 543 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 765 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2280 | 0.130 |
Why?
|
| Drug Therapy | 1 | 2015 | 16 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2015 | 14 | 0.130 |
Why?
|
| Cisplatin | 1 | 2015 | 77 | 0.130 |
Why?
|
| Sarcoma, Myeloid | 1 | 2014 | 3 | 0.120 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2015 | 69 | 0.120 |
Why?
|
| Geriatric Assessment | 3 | 2022 | 391 | 0.120 |
Why?
|
| Quality of Life | 1 | 2020 | 933 | 0.120 |
Why?
|
| Cystectomy | 1 | 2015 | 105 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2019 | 2282 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 21 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 28 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 114 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 200 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 607 | 0.090 |
Why?
|
| Registries | 2 | 2022 | 298 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 470 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1527 | 0.070 |
Why?
|
| Myeloablative Agonists | 1 | 2021 | 2 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 94 | 0.050 |
Why?
|
| Alabama | 1 | 2020 | 41 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 72 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2020 | 75 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2020 | 69 | 0.040 |
Why?
|
| Disabled Persons | 1 | 2020 | 105 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 757 | 0.040 |
Why?
|
| Health Status | 1 | 2022 | 399 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2019 | 84 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 1200 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 565 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 981 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2017 | 7 | 0.040 |
Why?
|
| Hospitalization | 1 | 2020 | 469 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2017 | 29 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 55 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2017 | 108 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2015 | 59 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 2151 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2014 | 17 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 8 | 0.030 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2014 | 50 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 885 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 70 | 0.030 |
Why?
|
| Microtubules | 1 | 2014 | 23 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2014 | 19 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 93 | 0.030 |
Why?
|
| Publication Bias | 1 | 2013 | 8 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 354 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 631 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 200 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 319 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 507 | 0.020 |
Why?
|